BioSpace News Archive

SimBioSys, the technology company that predicts tumor responses to therapy, today announced it will present nine posters at the AACR Annual Meeting 2022, taking place in New Orleans from April 8-13.

Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting , being held April 8 - 13, 2022 in New Orleans, Louisiana.

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate in the Canaccord Genuity Horizons in Oncology Conference.

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, will present new data on its lead drug candidate BTM-3566 at AACR 2022 taking place the 8th-13th of April in New Orleans.

Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights.

US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights.

BioNTech SE announced that it is one of the companies in Germany to be granted a pandemic preparedness contract by the Federal Republic of Germany.

IRLAB announces that the annual report for 2020 is published on the company´s website www.irlab.se.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today presented new preclinical data on the company’s lead oncology program, E-602, as well as data supporting Palleon’s novel bifunctional PD-L1-Targeted Sialidase, in two poster presentations at the American Association for Cancer Research Annual Meeting in New Orleans, La.

Asher Biotherapeutics (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced new preclinical data further demonstrating the profile of AB248, an engineered interleukin-2 (IL-2) immunotherapy that it intends to develop for the treatment of cancer.